Platinum Sponsor
AstraZeneca
AstraZeneca is leading a revolution in oncology with the ambition to provide cures for cancer in every form, following the science to understand cancer and all its complexities to discover, develop and deliver life-changing medicines to patients. The Company’s focus is on the most challenging cancers. It is through persistent innovation that AstraZeneca has built one of the most diverse portfolios and pipelines in the industry, with the potential to catalyse changes in the practise of medicine and transform the patient experience. AstraZeneca has the vision to redefine cancer care and, one day, eliminate cancer as a cause of death.
Gold Sponsor
Bayer: Science for a better life
Bayer is a global life science company with expertise in healthcare and agriculture. The company has had a presence in Australia since 1925 and has a long-term commitment to the health and nutrition of all Australians and New Zealanders.
As people live longer and the population continues to grow both locally and beyond, Bayer is one of the few companies that takes a comprehensive view of these issues. Guided by our purpose – Science for a better life – we apply our global scientific expertise in healthcare and agriculture to deliver innovations locally to help people and the planet thrive.
Bayer employs almost 900 people across Australia and New Zealand and is dedicated to servicing the needs of rural and remote communities. Bayer embraces and encourages its employees’ unique identities and advances a culture of inclusion and diversity across gender, LGBTQIA+, generations, disability and race.
At Bristol Myers Squibb, we are inspired by a single vision-transforming patients’ lives through science. Over the last several decades, our innovative medicines have improved how cancer is treated, making long-term survival a possibility for more patients. Across a broad range of solid tumours and blood disorders, we strive to help more patients with our medicines, scientific discovery and investigational research. Our scientists are exploring new frontiers in the future of personalised medicine, and through new digital platforms, we are converting decades of research and data into insights that sharpen the focus of our work. The breadth of our portfolio, deep scientific expertise, cutting-edge capabilities, and discovery platforms allow us to look at cancer from every angle, targeting the cancer directly and the environment it lives in, and amplifying the body’s ability to fight disease. We are committed to reflecting diverse patient populations in our clinical trials, and are collaborating with partners across the healthcare landscape to increase the speed and efficiency of our research.
As a leader in cancer care, BMS is working to empower all people with cancer to have a better future.
Silver Sponsor
Merck, a leading science and technology company, operates across life science, healthcare and electronics. More than 64,000 employees work to make a positive difference to millions of people’s lives every day by creating more joyful and sustainable ways to live. From providing products and services that accelerate drug development and manufacturing as well as discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2022, Merck generated sales of €22.2 billion in 66 countries.
Scientific exploration and responsible entrepreneurship have been key to Merck’s technological and scientific advances. This is how Merck has thrived since its founding in 1668. The founding family remains the majority owner of the publicly listed company. Merck holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the business sectors of Merck operate as MilliporeSigma in life science, EMD Serono in healthcare, and EMD Electronics in electronics.
At MSD, known as Merck & Co., In., Rahway, NJ, USA in the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and health future for all people and communities.
Bronze Sponsor
About Amplia Therapeutics
Amplia Therapeutics (ASX:ATX) is an Australian biotechnology company developing the best-in-class FAK inhibitor narmafotinib (AMP945). A Phase 1b/2a trial of narmafotinib in metastatic pancreatic cancer is underway (NCT05355298) where the drug is dosed prior to standard-of-care gemcitabine and nab-paclitaxel. Recruitment is open at sites in Melbourne, Sydney, and Brisbane.
About BeiGene
BeiGene is a global biotechnology company that is developing and commercializing innovative and affordable oncology medicines to improve treatment outcomes and access for far more patients worldwide. With a broad portfolio, we are expediting development of our diverse pipeline of novel therapeutics through our internal capabilities and collaborations. We are committed to radically improving access to medicines for far more patients who need them. Our growing global team of more than 8,500 colleagues spans five continents, with administrative offices in Beijing, China; Cambridge, U.S.; and Basel, Switzerland.
About Ferronova
Ferronova is an Australian biotechnology company commercialising magnetic nanoparticle and molecular imaging, that can be applied to a variety of medical applications. Their first-generation product aids in more accurate imaging, treatment and staging of gastric and oesophageal cancers. Ferronova’s mission is to ensure no cancer goes undetected. They aim to enable surgeons, oncologists and pathologists to maximise the use of their skills, support less invasive procedures and improve overall patient outcomes.
About Ipsen
Ipsen provides specialty medicines to Healthcare Professionals and their patients suffering from debilitating diseases. At Ipsen, our passion is improving the lives of patients. We do this by working together to build partnerships based on trust and mutual respect with Healthcare Professionals. Ipsen Pty Ltd is the Australian affiliate of a global biotech company.
About Pierre Fabre
The Pierre Fabre Group, founded by a pharmacist Pierre Fabre, is the second largest private pharmaceutical company in France. Owned by a government recognised public interest foundation, the Group is committed to designing and developing innovative solutions to contribute to the wellbeing of everyone through products across consumer health, dermo-cosmetics and pharmaceuticals.
In Australia, Pierre Fabre has prescription medicines in the area of oncology, dermo-cosmetics brand Eau Thermale Avene (a skincare range for all forms of sensitive skin), and Klorane (a haircare range formulated from carefully selected botanical ingredients).
About Roche
Roche New Zealand operates across two businesses, Pharmaceuticals and Diagnostics. Our aim is to enable New Zealanders access to our medicines and diagnostic tests to detect illnesses early, and to treat them with life-saving and life-changing medicines.
We have one purpose: to do now what patients need next.
About Servier
Servier is a privately owned pharmaceutical company, governed by a non-profit foundation that’s committed to therapeutic progress to serve patient needs. Servier has a long-standing commitment to research and development. Servier has significant investment in new products in early development in the areas of Oncology and Haematology with broad research and development platforms in cancer cell apoptosis and immuno-oncology.
Servier is proud to support innovative partnering programs with world class institutions including WEHI in Australia to further advance scientific understanding in the area of oncology.
About Specialised Therapeutics
Specialised Therapeutics commercialises new therapies and technologies for patients in Australia, New Zealand and across South-East Asia. Our GI oncology portfolio includes ABRAXANE® (nanoparticle albumin-bound paclitaxel) for metastatic breast cancer and pancreatic cancer, QINLOCK® (ripretinib) for gastrointestinal stromal tumours, PEMAZYRE® (pemigatinib) for cholangiocarcinoma and YONDELIS® (trabectedin) for advanced soft tissue sarcoma.